CytomX(US:CTMX) Globenewswire·2025-11-06 21:10Core Insights - CytomX Therapeutics is advancing its pipeline with a focus on CX-2051 and CX-801, with key updates expected in 2026 [1][2][3] Pipeline Developments - CX-2051 Phase 1 data update is scheduled for Q1 2026, with ongoing dose expansions in advanced colorectal cancer (CRC) [1][5] - A Phase 1b study combining CX-2051 with bevacizumab is set to begin in Q1 2026, aimed at informing late-phase development [5] - CX-801 has shown positive initial biomarker data in advanced melanoma, supporting its combination study with KEYTRUDA® [3][5] Financial Performance - As of September 30, 2025, the company reported cash, cash equivalents, and investments totaling $143.6 million, down from $158.1 million as of June 30, 2025 [7] - Total revenue for Q3 2025 was $6.0 million, a significant decrease from $33.4 million in Q3 2024, primarily due to the completion of obligations in collaborations [8] - Total operating expenses decreased to $21.7 million in Q3 2025 from $29.3 million in Q3 2024, with research and development expenses at $15.3 million [8][9] Corporate Updates - The company appointed Rachael Lester as Senior Vice President and Chief Business Officer in October 2025 [11] - CytomX has established collaborations with major companies in oncology, including Bristol Myers Squibb, Amgen, and Moderna, focusing on bispecific immunotherapies [11][12]